Related Experiment Video

Updated: Jun 20, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Circulating biomarkers for the diagnosis and prognosis of heart failure

D Tousoulis1, A M Kampoli, G Siasos

  • 1Athens University Medical School, 1st Cardiology Department, Hippokration Hospital, Greece. drtousoulis@hotmail.com

Current Medicinal Chemistry
|September 15, 2009
PubMed

Insights

New cardiac biomarkers offer improved heart failure management. A multi-marker approach using B-type natriuretic peptides and others enhances risk stratification and therapy optimization for heart failure patients.

Area of Science:

  • Cardiology
  • Biomarker Research

Background:

  • Heart failure (HF) management remains challenging despite therapeutic advances, contributing to significant morbidity and mortality.
  • Cardiac biomarkers are emerging as valuable tools for diagnosing and managing HF.
  • Current research explores various circulating biomarkers for their diagnostic and prognostic utility in HF.

Purpose of the Study:

  • To explore the potential of cardiac biomarkers in improving heart failure patient management.
  • To evaluate the utility of a multi-marker approach for better risk stratification and therapy optimization in HF.

Main Methods:

  • Review of preclinical, observational, and randomized prospective studies on candidate cardiac biomarkers.
  • Focus on B-type natriuretic peptides due to extensive existing knowledge and clinical experience.
  • Investigation into the combination of multiple biomarkers reflecting diverse pathophysiological aspects of HF.

Main Results:

  • B-type natriuretic peptides are the most studied biomarkers in heart failure.
  • Individual biomarkers may exhibit limitations in sensitivity and specificity.
  • A multi-marker strategy shows promise for enhanced risk assessment.

Conclusions:

  • Cardiac biomarkers represent a promising avenue for advancing heart failure care.
  • Combining multiple biomarkers can overcome the limitations of single markers.
  • A multi-marker approach is crucial for optimizing risk stratification and therapeutic strategies in heart failure management.

More Related Videos

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...